Trial Profile
A Phase 1 Study of LY2835219 in Japanese Patients With Advanced Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Aug 2020
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 07 Aug 2020 The study design is changed from single group assignment to randomized, parallel assignment and number of arms is changed from 1 to 3, representing 3 cohorts corresponding to 3 dosages of oral abemaciclib as- 100mg, 150mg and 200 mg.
- 16 Sep 2019 Status changed from active, no longer recruiting to completed.
- 16 Aug 2019 Planned End Date changed from 31 Dec 2019 to 21 Aug 2019.